MALVERN, PA, March 29 /PRNewswire-FirstCall/ - Novavax, Inc., (Nasdaq: NVAX) a specialty biopharmaceutical company, today announced that Dr. Rahul Singhvi, Vice-President Pharmaceutical Development and Manufacturing Operations, will be presenting at the Stephens Inc. 2005 Nanotechnology Investors Conference on Tuesday, April 5, 2005. Dr. Singhvi will provide an update on Novavax's novel micellar nanoparticle (MNP) technology and its potential for broad application. WHEN: Tuesday, April 5th, 2005 at 10:30 AM PST WHERE: Ritz Carlton Hotel, 1401 South Oak Knoll Ave, Pasadena, California HOW: The live broadcast of the presentation can be accessed through our website at www.novavax.com. After the presentation date, the webcast will be archived on our website for 90 days. Rahul Singhvi, Sc.D. Dr. Singhvi holds a Master and Doctorate of Science degree in Chemical Engineering from MIT and a Master of Business Administration from the Wharton School. Dr. Singhvi joined Novavax after 10 years experience with Merck & Co, where he most recently served as a Director within the Merck Manufacturing division. About Novavax Inc. Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on drug delivery and vaccine development. Novavax sells, markets, and distributes a line of women's health prescription pharmaceuticals through its specialty sales force calling on obstetricians and gynecologists throughout the United States including ESTRASORB(R), its topical emulsion for estrogen therapy. Novavax's micellar nanoparticle technology involves the use of patented oil and water nanoemulsions that it believes can be used as vehicles for the topical delivery of a wide variety of drugs and other therapeutic products, including hormones. In addition, Novavax conducts research and development on preventative and therapeutic vaccines and proteins for a variety of infectious diseases, including HIV, influenza, SARS and E-selectin tolerogen for the prevention of stroke. Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding product sales, future product development and related clinical trials and statements regarding future research and development. Novavax's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things, the following: general economic and business conditions; competition; unexpected changes in technologies and technological advances; ability to commercialize and manufacture products; results of clinical studies; research and development activities; changes in, or failure to comply with, governmental regulations; and the ability to obtain adequate financing in the future. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2004 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's Form 10K. Copies of the filing may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the SEC at www.sec.gov.
SOURCE Novavax Inc.